Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Web – sheet or filament bases; compositions of bandages; or...
Reexamination Certificate
2005-11-08
2011-12-20
Ghali, Isis (Department: 1611)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Web, sheet or filament bases; compositions of bandages; or...
C424S448000, C424S443000
Reexamination Certificate
active
08080261
ABSTRACT:
Gel compositions that contain 1-dichloro-2,4-dinitrobenzene (DNCB) are provided. Embodiments of the subject gel compositions include DNCB, an organic solvent and a viscosity agent, wherein the organic solvent and viscosity agent are inert with respect to the DNCB. Also provided are methods for using the subject compositions and kits for use in practicing the subject methods.
REFERENCES:
patent: 5304379 (1994-04-01), Cormier et al.
patent: 5597576 (1997-01-01), Genova et al.
patent: 5676968 (1997-10-01), Lipp et al.
patent: 5846559 (1998-12-01), Hopp
patent: 6455586 (2002-09-01), Kaplan et al.
patent: 6761900 (2004-07-01), Shudo et al.
patent: 2003/0221457 (2003-12-01), Cline et al.
patent: 2003/0221458 (2003-12-01), Cline et al.
patent: 2005/0284820 (2005-12-01), Luka
patent: 2005/0288409 (2005-12-01), Charbonneau et al.
patent: WO 02/072081 (2002-09-01), None
patent: 2004/037314 (2004-05-01), None
Stricker et al. “Dendritic Cells and Dinitrochlorobenzene (DNCB): A New Treatment Approach to AIDS.” Immunology Letters (1991) 29:191-196.
Stricker et al. “Pilot study of Topical Dinitrochlorobenzene (DNCB) in Human Immuno Deficiency Virus Infection,” Immunology Letters (1993) 36:1-6.
Stricker et al. “Topical Dinitrochlorobenzene in HIV Disease,” J. Am. Acad Dermatol. (1993) 28:796-797.
Stricker et al. “Clinical and Immunologic Evaluation of HIV-Infected Patients Treated with Dinitrochlorobenzene,” J. Am. Acad Dermatol.(1994) 31:462-466.
Stricker et al. “Improved Results of Delayed-Type Hypersensitivity Skin Testing in HIV-Infected Patients Treated with Topical Dinitrochlorobenzene,”J. Acad Dermatol. (1995) 33:608-611.
Stricker and Goldberg “Safety of Topical Dinitrochlorbenzene,” The Lancet (1995) vol. 346 pp. 1293.
Stricker et al. “Improved Results of Delayed-Type Hypersensitivity Skin Testing in HIV-Infected Patients Treated with Topical Dinitrochlorobenzene,” J. Am. Acad Dermatol (1996) 35:491-493.
Stricker et al. “Decrease in Viral Load Associated with Topical Dinitrochlorobenzene Therapy in HIV Disease,” Res Virol. (1997) 148:343-348.
Traub et al. “Topical Immune Modulation with Dinitrochlorobenzene (DNCB) in HIV Disease: A Controlled Trial from Brazil,” Dermatology (1997) 195:369-373.
Stricker et al. “Topical Immune Modulation (TIM): A Novel Approach to the Immunotherapy of Systemic Disease,” Immunology Letters (1997) 59:145-150.
Oracion et al. “DNCB Treatment of HIV-Infected Patients Leads to Beneficial Immunologic Outcomes, Reduced Viral Load, and Improved Measures of Quality-of-Life,” J. Invest Dermatol. (1998) 110:476.
Bozicevic Field & Francis LLP
Field Bret E.
Ghali Isis
Teikoku Pharma USA Inc.
LandOfFree
1-chloro-2,4-dinitrobenzene non-aqueous gel compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1-chloro-2,4-dinitrobenzene non-aqueous gel compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-chloro-2,4-dinitrobenzene non-aqueous gel compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4313468